近日elliptical，F(xiàn)DA官網(wǎng)發(fā)布了關(guān)于阿斯利康召回替卡格雷elliptical，該公司將替卡格雷與其生產(chǎn)elliptical的另外一個產(chǎn)品雷西納得混淆，裝在同一個瓶子里并已放行銷售。

　　有關(guān)該報道elliptical的原文摘譯如下：

　　AstraZeneca today announced that the Company is notifying physicians and consumers that it is voluntarily recalling one lot of professional (physician) sample bottles containing eight tablets of BRILINTA? (ticagrelor) 90mg tablets as a precautionary measure. This voluntary recall follows a report that a professional sample bottle containing eight tablets of BRILINTA 90mg also contained another medicine called ZURAMPIC? (lesinurad) 200 mg tablets which is also manufactured by AstraZeneca.

　　阿斯利康今天宣布該公司正式通知醫(yī)生和消費者，他們正主動召回一批專業(yè)（醫(yī)生）樣品瓶，包含8片BRILINTA?（替卡格雷）90mg/片。該主動召回附帶一個報告：8片/瓶的BRILINTA（替卡格雷）90mg/片里面還裝有另外一個藥品ZURAMPIC?雷西納得200mg/片。

　　Unintentional dosing with ZURAMPIC has the potential to lead to adverse renal effects including acute renal failure which is more common when ZURAMPIC is given alone as it should be used in combination with a xanthine oxidase inhibitor.

　　服用ZURAMPIC有潛在的導(dǎo)致腎功能不良，包括急性腎功能衰竭，這在單獨服用ZURAMPIC時比其與黃嘌呤氧化酶抑制劑組合使用時更加明顯。

　　Missed doses of BRILINTA increases the risk of heart attack and stroke. People who are treated with a stent and miss doses of BRILINTA have a higher risk of getting a blood clot in the stent, having a heart attack, or death.

　　而BRILINTA給藥不足將增加心肌梗死和中風(fēng)的危險。使用血管內(nèi)支架治療的人群在BRILINTA給藥不足的情況下，有更高的風(fēng)險導(dǎo)致血管支架血栓、心肌梗死，甚至死亡。

　　BRILINTA 90 mg tablets are supplied as a round, biconvex, yellow, film-coated tablet, and imprinted with 90 above a T on one side of the pill. ZURAMPIC tablets 200 mg are blue in color and elliptical/oval in shape. They are imprinted with LES200 on one side of the pill.

　　BRILINTA?（替卡格雷）90mg/片是圓形、兩面凸起、黃色、薄膜包衣片，一面印有“90”和“T”字樣。ZURAMPIC?雷西納得200mg/片是藍色橢圓型的，一面印有“LES200”字樣。

　　BRILINTA?（替卡格雷）

ZURAMPIC?（雷西納得）

　　來源：GMP辦公室